Albuminuria is an important factor predicting cardiovascular risk in patients with type 2 diabetic nephropathy. Reducing albuminuria in the first 6 months appears to afford cardiovascular protection in these patients.
Wouter B.A. Eijkelkamp, Zhongxin Zhang, Giuseppe Remuzzi, Hans‐Henrik Parving, Mark E. Cooper, William F. Keane, Shahnaz Shahinfar, Gilbert W. Gleim, Barry M. Brenner, Dick de Zeeuw
Liffert Vogt, Carlos Chiurchiu, Harbajan Chadha‐Boreham, Parisa Danaietash, Jasper Dingemanse, Samy Hadjadj, Henry Krum, Gerjan Navis, Eric Neuhart, Aneliya Parvanova, Piero Ruggenenti, A. J. J. Woittiez, Reuven Zimlichman, Giuseppe Remuzzi, Dick de Zeeuw
Dick de Zeeuw, Blai Coll, Dennis L. Andress, John J. Brennan, Hui Tang, Mark T. Houser, Ricardo Correa‐Rotter, Donald E. Kohan, Hiddo J.L. Heerspink, Hirofumi Makino, Vlado Perkovic, Yili Pritchett, Giuseppe Remuzzi, Sheldon W. Tobe, Robert Toto, Giancarlo Viberti, Hans‐Henrik Parving
William F. Keane, Zhongxin Zhang, Paulette A. Lyle, Mark E. Cooper, Dick de Zeeuw, Jean-Pierre Grunfeld, James P. Lash, Janet B. McGill, William E. Mitch, Giuseppe Remuzzi, Shahnaz Shahinfar, Steven Snapinn, Robert D. Toto, Barry M. Brenner
Wouter B.A. Eijkelkamp, Zhongxin Zhang, Barry M. Brenner, Mark E. Cooper, Richard B. Devereux, Björn Dahlöf, Hans Ibsen, William F. Keane, Lars Lindholm, Michael Hecht Olsen, Hans‐Henrik Parving, Giuseppe Remuzzi, Shahnaz Shahinfar, Steven Snapinn, Kristian Wachtell, Dick de Zeeuw
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.